Effects of tetrandrine combined with acetylcysteine on exercise tolerance, pulmonary function and serum TNF-β1 and MMP-7 in silicosis patients

Zhang,Jing; Wang,Yingchun; Zhang,Shujuan; Li,Jing; Fang,Hong

doi:10.3892/etm.2020.8431

Effects of tetrandrine combined with acetylcysteine on exercise tolerance, pulmonary function and serum TNF-β1 and MMP-7 in silicosis patients

Authors:
- Jing Zhang
- Yingchun Wang
- Shujuan Zhang
- Jing Li
- Hong Fang
View Affiliations

Affiliations: Department of Pharmacy, Maternal and Child Health Care Hospital of Zhangqiu District, Jinan 250200, P.R. China, Department of Pharmacy, Yantaishan Hospital, Yantai 264000, P.R. China, Occupational Disease Department, Branch of Tai'an City Central Hospital, Tai’an 271000, P.R. China, Department of Surgery, The People's Hospital of Zhangqiu Area, Jinan 250200, P.R. China, Department of Hepatobiliary Surgery, Weifang Traditional Chinese Hospital, Weifang 261041, P.R. China
Published online on: January 29, 2020 https://doi.org/10.3892/etm.2020.8431
Pages: 2195-2201
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the study was to investigate the effects of tetrandrine combined with acetylcysteine on exercise tolerance, pulmonary function, transforming growth factor‑β1 (TGF-β1) and matrix metalloproteinase 7 (MMP-7) in silicosis patients. A retrospective analysis was performed on 149 silicosis patients admitted to the Maternal and Child Health Care Hospital of Zhangqiu District between August, 2015 and September, 2017. Of the 149 patients, 70 patients treated with acetylcysteine comprised the control group, and 79 treated with tetrandrine combined with acetylcysteine constituted the study group. The concentrations of serum TGF-β1 and MMP-7 before and after treatment were detected by enzyme-linked immunosorbent assay (ELISA), and the exercise tolerance and pulmonary function were compared. Chest distress, chest pain, cough, expectoration and dyspnea in the two groups were relieved after treatment, and the improvement rates of chest distress, chest pain and dyspnea in the study group were significantly higher than those in the control group (P<0.05). Before treatment, there was no significant difference in the results of the 6-minute walk test (6MWT) between the two groups (P>0.05). After treatment, the 6MWT in the two groups was significantly increased (P<0.05), and the improvement effect in the study group was more marked than that in the control group (P<0.05). There was no significant difference in the pulmonary function indexes between the two groups before treatment (P>0.05). Before treatment, there was no significant difference in serum TGF-β1 and MMP-7 expression levels between the two groups (P>0.05). By contrast, after treatment, the levels in the two groups were significantly decreased, with the levels in the study group being significantly lower than that the control group (P<0.05). In conclusion, tetrandrine combined with acetylcysteine can improve pulmonary function and exercise tolerance of patients with silicosis by inhibiting the expressions of TGF-β1 and MMP-7, thus improving clinical efficacy.

View Figures

View References

1	Chen S, Yuan J, Yao S, Jin Y, Chen G, Tian W, Xi J, Xu Z, Weng D and Chen J: Lipopolysaccharides may aggravate apoptosis through accumulation of autophagosomes in alveolar macrophages of human silicosis. Autophagy. 11:2346–2357. 2015. View Article : Google Scholar : PubMed/NCBI
2	Castranova V and Vallyathan V: Silicosis and coal workers' pneumoconiosis. Environ Health Perspect. 108:675–684. 2000. View Article : Google Scholar : PubMed/NCBI
3	Murtha LA, Morten M, Schuliga MJ, Mabotuwana NS, Hardy SA, Waters DW, Burgess JK, Ngo DT, Sverdlov AL, Knight DA, et al: The role of pathological aging in cardiac and pulmonary fibrosis. Aging Dis. 10:419–428. 2019. View Article : Google Scholar : PubMed/NCBI
4	Mei L, Chen Y, Wang Z, Wang J, Wan J, Yu C, Liu X and Li W: Synergistic anti-tumour effects of tetrandrine and chloroquine combination therapy in human cancer: A potential antagonistic role for p21. Br J Pharmacol. 172:2232–2245. 2015. View Article : Google Scholar : PubMed/NCBI
5	Kolahian S, Fernandez IE, Eickelberg O and Hartl D: Immune mechanisms in pulmonary fibrosis. Am J Respir Cell Mol Biol. 55:309–322. 2016. View Article : Google Scholar : PubMed/NCBI
6	Liu T, Liu X and Li W: Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy. Oncotarget. 7:40800–40815. 2016.PubMed/NCBI
7	Wynn TA: Integrating mechanisms of pulmonary fibrosis. J Exp Med. 208:1339–1350. 2011. View Article : Google Scholar : PubMed/NCBI
8	Strieter RM and Mehrad B: New mechanisms of pulmonary fibrosis. Chest. 136:1364–1370. 2009. View Article : Google Scholar : PubMed/NCBI
9	Sun W, Tang H, Gao L, Sun X, Liu J, Wang W, Wu T and Lin H: Mechanisms of pulmonary fibrosis induced by core fucosylation in pericytes. Int J Biochem Cell Biol. 88:44–54. 2017. View Article : Google Scholar : PubMed/NCBI
10	Warburton D, Shi W and Xu B: TGF-β-Smad3 signaling in emphysema and pulmonary fibrosis: An epigenetic aberration of normal development? Am J Physiol Lung Cell Mol Physiol. 304:L83–L85. 2013. View Article : Google Scholar : PubMed/NCBI
11	Aono Y, Ledford JG, Mukherjee S, Ogawa H, Nishioka Y, Sone S, Beers MF, Noble PW and Wright JR: Surfactant protein-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury. Am J Respir Crit Care Med. 185:525–536. 2012. View Article : Google Scholar : PubMed/NCBI
12	Doyle TJ, Pinto-Plata V, Morse D, Celli BR and Rosas IO: The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases. Chest. 142:1027–1034. 2012. View Article : Google Scholar : PubMed/NCBI
13	Morrison MI, Pither TL and Fisher AJ: Pathophysiology and classification of primary graft dysfunction after lung transplantation. J Thorac Dis. 9:4084–4097. 2017. View Article : Google Scholar : PubMed/NCBI
14	Pei JS, Chou AK, Hsu PC, Tsai CW, Chang WS, Wu MF, Wu MH, Hsia TC, Cheng SP and Bau DT: Contribution of matrix metalloproteinase-7 genotypes to the risk of non-solid tumor, childhood leukemia. Anticancer Res. 37:6679–6684. 2017.PubMed/NCBI
15	Martinez FJ, Chisholm A, Collard HR, Flaherty KR, Myers J, Raghu G, Walsh SL, White ES and Richeldi L: The diagnosis of idiopathic pulmonary fibrosis: Current and future approaches. Lancet Respir Med. 5:61–71. 2017. View Article : Google Scholar : PubMed/NCBI
16	Song JW, Do KH, Jang SJ, Colby TV, Han S and Kim DS: Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest. 143:1422–1429. 2013. View Article : Google Scholar : PubMed/NCBI
17	Rosas IO, Goldberg HJ, Collard HR, El-Chemaly S, Flaherty K, Hunninghake GM, Lasky JA, Lederer DJ, Machado R, Martinez FJ, et al: A phase II clinical trial of low-dose inhaled carbon monoxide in idiopathic pulmonary fibrosis. Chest. 153:94–104. 2018. View Article : Google Scholar : PubMed/NCBI
18	Flaherty KR, Andrei AC, Murray S, Fraley C, Colby TV, Travis WD, Lama V, Kazerooni EA, Gross BH, Toews GB, et al: Idiopathic pulmonary fibrosis: Prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med. 174:803–809. 2006. View Article : Google Scholar : PubMed/NCBI
19	Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N and Miyatake K: Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 161:487–492. 2000. View Article : Google Scholar : PubMed/NCBI
20	Ma J, Zhou Y, Li W, Xiao L, Yang M, Tan Q, Xu Y and Chen W: Association between plasma HMGB-1 and silicosis: A case-control study. Int J Mol Sci. 19:40432018. View Article : Google Scholar
21	Wang SX, Liu P, Wei MT, Chen L, Guo Y, Wang RY, Tu ZG and Liang XC: Roles of serum clara cell protein 16 and surfactant protein-D in the early diagnosis and progression of silicosis. J Occup Environ Med. 49:834–839. 2007. View Article : Google Scholar : PubMed/NCBI
22	Racanelli AC, Kikkers SA, Choi AMK and Cloonan SM: Autophagy and inflammation in chronic respiratory disease. Autophagy. 14:221–232. 2018. View Article : Google Scholar : PubMed/NCBI
23	Dong J and Ma Q: Macrophage polarization and activation at the interface of multi-walled carbon nanotube-induced pulmonary inflammation and fibrosis. Nanotoxicology. 12:153–168. 2018. View Article : Google Scholar : PubMed/NCBI
24	Raha S, Kim SM, Lee HJ, Lee SJ, Heo JD, Venkatarame Gowda Saralamma V, Ha SE, Kim EH, Mun SP and Kim GS: Essential oil from Korean Chamaecyparis obtusa leaf ameliorates respiratory activity in Sprague Dawley rats and exhibits protection from NF-κB-induced inflammation in WI38 fibroblast cells. Int J Mol Med. 43:393–403. 2019.PubMed/NCBI
25	Zeidler P, Hubbs A, Battelli L and Castranova V: Role of inducible nitric oxide synthase-derived nitric oxide in silica-induced pulmonary inflammation and fibrosis. J Toxicol Environ Health A. 67:1001–1026. 2004. View Article : Google Scholar : PubMed/NCBI
26	Duru N, Wolfson B and Zhou Q: Mechanisms of the alternative activation of macrophages and non-coding RNAs in the development of radiation-induced lung fibrosis. World J Biol Chem. 7:231–239. 2016. View Article : Google Scholar : PubMed/NCBI
27	Liu L, Carron B, Yee HT, Yie TA, Hajjou M and Rom W: Wnt pathway in pulmonary fibrosis in the bleomycin mouse model. J Environ Pathol Toxicol Oncol. 28:99–108. 2009. View Article : Google Scholar : PubMed/NCBI
28	Wang X and Khalil RA: Matrix metalloproteinases, vascular remodeling, and vascular disease. Adv Pharmacol. 81:241–330. 2018. View Article : Google Scholar : PubMed/NCBI
29	Gharib SA, Johnston LK, Huizar I, Birkland TP, Hanson J, Wang Y, Parks WC and Manicone AM: MMP28 promotes macrophage polarization toward M2 cells and augments pulmonary fibrosis. J Leukoc Biol. 95:9–18. 2014. View Article : Google Scholar : PubMed/NCBI
30	Mohammed FF, Smookler DS and Khokha R: Metalloproteinases, inflammation, and rheumatoid arthritis. Ann Rheum Dis. 62:ii43–ii47. 2003. View Article : Google Scholar : PubMed/NCBI
31	Li Q, Park PW, Wilson CL and Parks WC: Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell. 111:635–646. 2002. View Article : Google Scholar : PubMed/NCBI
32	McGuire JK, Li Q and Parks WC: Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am J Pathol. 162:1831–1843. 2003. View Article : Google Scholar : PubMed/NCBI
33	Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, Lollini L, Morris D, Kim Y, DeLustro B, et al: Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA. 99:6292–6297. 2002. View Article : Google Scholar : PubMed/NCBI
34	Datta A, Scotton CJ and Chambers RC: Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol. 163:141–172. 2011. View Article : Google Scholar : PubMed/NCBI
35	Craig VJ, Zhang L, Hagood JS and Owen CA: Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 53:585–600. 2015. View Article : Google Scholar : PubMed/NCBI
36	Lee SH, Yeo Y, Kim TH, Lee HL, Lee JH, Park YB, Park JS, Kim YH, Song JW, Jhun BW, et al Korean Interstitial Lung Diseases Study Group, : Korean guidelines for diagnosis and management of interstitial lung diseases: Part 2. Idiopathic pulmonary fibrosis. Tuberc Respir Dis (Seoul). 82:102–117. 2019. View Article : Google Scholar : PubMed/NCBI
37	Benjamin MM and Khalil RA: Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. Exp Suppl. 103:209–279. 2012.PubMed/NCBI
38	Miao RM, Sun XF, Zhang YY, Wu W, Fang ZH, Zhao R, Zhao DK, Qian GL and Ji J: Clinical efficacy of tetrandrine combined with acetylcysteine effervescent tablets in treatment of silicosis. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 31:857–858. 2013.(In Chinese). PubMed/NCBI
39	Xiao Y, Xia H, Zhu L, Li X, Chen R, Yin X, Jiang Z, Feng L, Chen J, Yu M, et al: Study on the therapeutic effects of tetrandrine combined with N-acetylcysteine on experimental silicosis of rats. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 33:519–522. 2015.(In Chinese). PubMed/NCBI
40	Ning JX, Zhang LP and Cui Y: Evaluation of clinical efficacy of tretrandrine combined with acetylcysteine effervescent tablets in the treatment of silicosis. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 35:298–299. 2017.(In Chinese). PubMed/NCBI
41	Miao RM, Zhang XT, Yan YL, He EQ, Guo P, Zhang YY, Zhao DK, Yang ZG, Chen J, Yao MY, et al: Change of serum TGF-beta1 and TNF-alpha in silicosis patients. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 29:606–607. 2011.(In Chinese). PubMed/NCBI
42	Sadikot RT, Blackwell TS, Christman JW and Prince AS: Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med. 171:1209–1223. 2005. View Article : Google Scholar : PubMed/NCBI
43	Hill MR, Briggs L, Montaño MM, Estrada A, Laurent GJ, Selman M and Pardo A: Promoter variants in tissue inhibitor of metalloproteinase-3 (TIMP-3) protect against susceptibility in pigeon breeders' disease. Thorax. 59:586–590. 2004. View Article : Google Scholar : PubMed/NCBI